As of 4:00pm ET
| +0.14 / +0.36%|
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The Corporate or Other segment covers other expenses not directly attributable to the segments and certain intercompany transactions of the firm. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
|Heather M. Bresch||Chief Executive Officer & Executive Director|
|Rajiv Malik||President & Executive Director|
|Haribabu Bodepudi||Chief Operating Officer|
|Kenneth Scott Parks||Chief Financial Officer|
|Jonathan R. Collins||Vice President & Head-eCommerce|